Preclinical feature articles

  1. It Is Time To Require Human-Relevant Efficacy Evidence Before First-In-Human Trials 8/26/2026

    Why, when human-relevant evidence of likely efficacy can be generated before a trial begins, is it not evaluated before patients are exposed?

  2. To Prevent Parkinson's Disease, We Need New Biomarkers 6/16/2026

    Parkinson's disease research has shifted toward prevention and prodromal intervention but success with disease-modifying and preventive therapies depends on validated PD-specific biomarkers. AC Immune Cofounder and CEO Andrea Pfeifer explains.

  3. Why Tolerability Will Drive The Next Wave Of Obesity Treatments 5/29/2026

    For the next generation of obesity medicines, enhancing how patients experience therapy will inform discovery and development efforts and may ultimately determine long-term success.

  4. Synaptic Regeneration And The Future Of Alzheimer's R&D 5/22/2026

    For too long, treating Alzheimer’s disease has been a case of “managed decline.” We need to move beyond slowing disease progression toward achieving tangible functional recovery.

  5. There's A Gap In Brain Tumor Research — Here's How We Fix It 4/9/2026

    Brain tumors are some of the most biologically complex and least improved indications. Biochemistry researcher and scientist Catherine Bladen, Ph.D., argues sustained focus is a key to driving real-world progress.

  6. Could Moving To This Swiss Life Sciences Hub Be In Your Company's Future? 1/15/2026

    Basel Area Business & Innovation CEO Christof Klöpper discusses how the Basel Area Life Sciences Supercluster supports discovery through commercialization.

  7. The Rise Of Antimicrobial Resistance And Strategic Research Imperatives For 2026 12/26/2025

    Antimicrobial resistance (AMR) has increasingly worried public health officials and researchers alike in 2025. Now, in 2026, TAXI Pharmaceutical President and CEO Gregory G. Mario, MBA, is calling for more targeted approaches and the integration of AI for quicker discovery and development.

  8. How The U.S. Can Beat China In Biotech 11/3/2025

    Lumen Bioscience's Brian Finrow breaks down China's biotech playbook and explores ways the U.S. can adapt it for its own continued success.

  9. How Redefining The Diagnostic Odyssey Can Lead To Better Patient Outcomes 10/22/2025

    Patient advocate Wendy Cogan calls for improved diagnostic pathways as a means to better clinical trial recruitment and design while telling the journey of her late husband's journey to a corticobasal degeneration(CBD)-frontal behavioral-spatial syndrome (FBS) diagnosis.

  10. Careful Outsourcing Proves Key To Targeted Protein Degradation Drug Development 10/21/2025

    Discover how partnerships — especially with capable CROs — as well as resilient supply chains, digital enablement, regulatory foresight, and specialized talent impact the success of targeted protein degradation therapies.